Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 4Active not recruiting 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6Genitourinary 1

Conditions

Stomach Neoplasms 6Urinary Bladder Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous-Cell Non-Small-Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Gastrointestinal Neoplasms 1Gastric or Gastroesophageal Cancer 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of Lung 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × bemarituzumab × Clear all
NCT05052801 2026-05-27

FORTITUDE-101

Amgen

Phase 3 Completed
547 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05111626 2025-12-15

FORTITUDE-102

Amgen

Phase 3 Active not recruiting
515 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05322577 2025-12-05

FORTITUDE-103

Amgen

Phase 1/2 Active not recruiting
72 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02318329 2024-06-04

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Five Prime Therapeutics, Inc.

Phase 1 Completed
79 enrolled 21 charts
GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

NCT03343301 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 1 Completed
12 enrolled 17 charts
Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT03694522 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 2 Completed
155 enrolled 19 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡